Regenerative Medicine Products Business: No Products Launched and R&D Investment Front-Loaded
First written in FY2023. 1 of 7 entries say "Cited as achieved", first in 2026-05-27. Latest entry: 2026-08-13.
The whole theme swung hardest in 2021: 5 of 10 companies on the "Worse" side.
2 other companies' latest entry also says "Mitigated".
- FY2025Segment loss narrowsAnnual report
「For the fiscal year, revenue was ¥0 million, down 10.8% year on year, while the segment loss was ¥407 million, compared with a segment loss of ¥434 million in the previous fiscal year, mainly due to a decrease in fees paid resulting from delays in the timing of R&D expenditure.」
Revenue from regenerative medicine products remained virtually zero, and the structure of having no launched products continued, while the segment loss narrowed from ¥434 million to ¥407 million. - FY2025-H1Discontinuation of regenerative medicine product development and slight reduction in lossAnnual report
「For the interim accounting period, revenue was ¥0 million, up 12.0% year on year, while the segment loss was ¥216 million, compared with a segment loss of ¥219 million in the same period of the previous year, mainly due to a decrease in R&D expenses.」
Revenue from the regenerative medicine products business remained at ¥0 million, while the segment loss narrowed slightly from ¥219 million to ¥216 million due to lower R&D expenses. - FY2024-Q2Revenue decline and narrower segment lossAnnual report
「For the cumulative second quarter, revenue was ¥0 million, down 39.7% year on year, while the segment loss was ¥219 million, compared with a segment loss of ¥225 million in the same period of the previous year, due to a decrease in R&D expenses.」
Revenue from the regenerative medicine products business fell 39.7% year on year to ¥0 million, while the segment loss narrowed from ¥225 million to ¥219 million due to lower R&D expenses. - FY2024-Q1Decline in revenue and increase in R&D expensesAnnual report
「For the cumulative first quarter, revenue was ¥0 million, down 64.4% year on year, while the segment loss was ¥115 million, compared with a segment loss of ¥107 million in the same period of the previous year, mainly due to an increase in R&D expenses.」
Quarterly revenue from the regenerative medicine products business fell 64.4% year on year to virtually zero, while the segment loss widened from ¥107 million to ¥115 million due mainly to higher R&D expenses. The structure of having no launched products and investing in R&D ahead of commercialisation continues. - FY2023First statedAnnual report
「Revenue from the regenerative medical products business was ¥0.4 million, up 111.2% from the previous fiscal year. Because no regenerative medical products have yet been commercially launched, revenue currently consists only of license income, while R&D investment for manufacturing and marketing regenerative medical products is being incurred ahead of revenue generation.」
The regenerative medical products business has no marketed products; revenue is limited to license income and R&D investment is being incurred ahead of commercialization.